ÂÜÀòÂÒÂ×

Elliot Goldstein brings a unique track record in the clinical, regulatory, and commercial development of new pharmaceuticals. Dr. Goldstein began his career with Sandoz Pharmaceuticals (now Novartis), a fourteen-year period on drug development in France, Basel, Switzerland Global Headquarters, including as Head of Clinical R&D in the United States. He subsequently held positions as SVP of Strategic Product Development at SmithKline Beecham (now GSK), CEO of British Biotech (Oxford, UK), Chief Operating Officer and Chief Medical Officer of Maxygen, and President and CMO of startup biotech devoted to the development of biosimilar monoclonal antibodies. Dr. Goldstein holds an MD from the University Aix-Marseille II, Marseille, France, and a BSc from McGill University, Montreal.